Download this poster to share.
The REDOSE 2.0 study aims to better understand the concentrations and side effects of bictegravir, a commonly prescribed antiretroviral medication. This medication is part of a regimen called Biktarvy. Participation in this study is voluntary and you can withdraw at any time. All information collected will remain confidential.
You may be eligible for REDOSE 2.0 if you are:
- living with HIV
- on a HIV treatment regimen that contains bictegravir. This is a part of a common combination antiretroviral treatment called biktarvy®
- between the ages of 19 and 50 years, or 60 years and older;
- able to communication in English;
- undetectable (e.g., HIV viral load<40 copies/mL) within the last 14 days;
If you meet all these criteria, you are eligible to be a part of our REDOSE 2.0 study.